食管胃交界处肠上皮化生的内镜监测:一项决策模型分析
该研究建立决策分析模型,比较50岁非异型增生性食管胃交界处肠上皮化生(EGJIM)患者四种内镜监测策略(不监测、每3年、每5年、3年时1次)在4种进展情景下的成本效果。结果显示监测的成本效果取决于EGJIM进展为癌的速率:最低进展率(情景A,0.01%)下所有监测策略均不具成本效果;中等进展情景下3年时1次监测具成本效果;情景D(0.22%)下每5年监测具成本效果。
要点
- 监测成本效果取决于EGJIM进展率,低进展率(0.01%)下所有监测策略均不具成本效果。
- 情景B(0.05%)与情景C(0.12%)下,3年时1次监测具成本效果。
- 情景D(0.22%)下每5年监测具成本效果,每质量调整生命年77,695美元。
核心结论
- 内镜监测费用高且可能造成伤害,但低强度纵向监测(每5年)在EGJAC发病率较高人群中具成本效果。
- 在低发病率人群中,不监测或对EGJIM患者行1次内镜监测具成本效果。
- 需要未来研究更好地了解EGJIM的自然史、识别进展的危险因素并指导合适的监测策略。
研究设计与样本
- 决策分析模型,比较50岁非异型增生性EGJIM患者诊断后的四种内镜监测策略:不监测(标准治疗)、每3年内镜、每5年内镜、3年时1次内镜。
- 建立4种进展情景以反映不确定性:A(年癌症发病率0.01%)、B(0.05%)、C(0.12%)、D(0.22%)。
主要发现
- 内镜监测的成本效果取决于EGJIM进展为癌的速率。
- 最低进展率(情景A,0.01%)下,无监测策略具成本效果。
- 中等进展情景下,3年时1次监测具成本效果:情景B(0.05%)为每质量调整生命年30,989美元,情景C(0.12%)为每质量调整生命年16,526美元。
- 情景D(0.22%)下,每5年监测具成本效果,为每质量调整生命年77,695美元。
关键数值与推荐
- 情景B(0.05%)下3年时1次监测为每质量调整生命年30,989美元,情景C(0.12%)下为每质量调整生命年16,526美元。
- 情景D(0.22%)下每5年监测为每质量调整生命年77,695美元。
- 情景A(0.01%)下无监测策略具成本效果。
临床怎么用
- 作者认为,在EGJAC发病率较高人群中,低强度纵向监测(每5年)具成本效果。
- 作者认为,在低发病率人群中,不监测或1次内镜监测具成本效果。
- 作者提出需要未来研究了解EGJIM自然史、识别进展危险因素并指导合适的监测策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The incidence of esophagogastric junction adenocarcinoma (EGJAC) has been rising. Intestinal metaplasia of the esophagogastric junction (EGJIM) is a common finding in gastroesophageal reflux (irregular Z-line) and may represent an early step in the development of EGJAC in the West. Worldwide, EGJIM may represent progression along the Correa cascade triggered by Helicobacter pylori . We sought to evaluate the cost-effectiveness of endoscopic surveillance of EGJIM. METHODS: We developed a decision analytic model to compare endoscopic surveillance strategies for 50-year-old patients after diagnosis of non-dysplastic EGJIM: (i) no surveillance (standard of care), (ii) endoscopy every 3 years, (iii) endoscopy every 5 years, or (iv) 1-time endoscopy at 3 years. We modeled 4 progression scenarios to reflect uncertainty: A (0.01% annual cancer incidence), B (0.05%), C (0.12%), and D (0.22%). RESULTS: Cost-effectiveness of endoscopic surveillance depended on the progression rate of EGJIM to cancer. At the lowest progression rate (scenario A, 0.01%), no surveillance strategies were cost-effective. In moderate progression scenarios, 1-time surveillance at 3 years was cost-effective, at $30,989 and $16,526 per quality-adjusted life year for scenarios B (0.05%) and C (0.12%), respectively. For scenario D (0.22%), surveillance every 5 years was cost-effective at $77,695 per quality-adjusted life year. DISCUSSION: Endoscopic surveillance is costly and can cause harm; however, low-intensity longitudinal surveillance (every 5 years) is cost-effective in populations with higher EGJAC incidence. No surveillance or 1-time endoscopic surveillance of patients with EGJIM was cost-effective in low-incidence populations. Future studies to better understand the natural history of EGJIM, identify risk factors of progression, and inform appropriate surveillance strategies are required.
引用
- Yoon JY, Lim F, Shah SC, et al. Endoscopic Surveillance of Intestinal Metaplasia of the Esophagogastric Junction: A Decision Modeling Analysis. Am J Gastroenterol. 2024. PMID: 38275234. doi:10.14309/ajg.0000000000002672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。